Market Potential Cyrano targets a large, underserved market for smell and taste dysfunction across the US and Europe, with no approved therapies. The near term Phase 2 results and potential regulatory approval would create multiple sales opportunities for licensing, co commercialization, or exclusive distribution partnerships with ENT clinics, hospitals, and payer networks to drive rapid adoption.

Clinical Momentum A Phase 2 trial conducted at 14 sites with a readout expected in Q1 2025 demonstrates clinical momentum and near term milestones ideal for engaging key opinion leaders, early access programs, and potential co development partners to accelerate market entry.

Partnership Signals Funding activity including Series A and Series B rounds, plus engagement at industry events like BIO International Convention, signals strong partner interest. This creates openings for strategic alliances around manufacturing, commercialization rights, and regional licensing deals with larger pharmaceutical companies.

Scale Readiness With a lean team, Cyrano can leverage CROs, CMOs, and distribution partners to scale manufacturing, regulatory submissions, and market access activities, presenting outbound sales opportunities for contract manufacturers and specialty distributors to support post approval scale.

Competitive Position Cyrano holds a first in class intranasal formulation for smell restoration with a unique delivery profile, positioning it to capture early adopters among ENT clinics, smell rehabilitation centers, and post viral clinics, while exploring expansion into related olfactory disorders.